Indication intelligence, analysis and sector perception

RegMed/Cell and Gene Therapy Earnings Scorecard Q3/20 LPS Results

November 28, 2020 10:47am

A scorecard of 34 earnings releases and 1 acquisition of 35 covered companies

The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"

COMPANY	SYMBOL	NET INCOME	Q3/20 LOSS	Q3/20 LPS	Q2/20 CASH	RUNWAY
Chinook Therapeutics formerly, Aduro Biotech (ADRO)	KDNY		–$14.5 M	–$0.90	$74.31 M	2022
Alnylam Pharmaceuticals	ALNY		–$253.2 M	–$2.18	$1.83 Billion	N/A
Applied Genetic Technologies	AGTC		–$15.4 M	–$0.60	$66.6 M	04/21
Athersys, Inc.	ATHX		–$22.5 M	–$0.11	$61.7 M	Q4/21
Adverum Biotechnologies	ADVM		–$27.8 M	–$0.31	$454.5 M	mid-2022
AxoGen	AXGN		–$1.5 M	–$0.04	$106.7 M	2022
Bellicum Pharmaceuticals	BLCM		–$900 K	–$0.18	$54.6 M	Q2/22
BioLife Solutions	BLFS		–$1.1 M	–$0.04	$109 M	2024
Biostage	BSTG		–$700 K	–$0.07	$2 M	Q1/21
bluebird bio	BLUE		-$194.7 M	–$2.94	$1.44 B	2023
Brainstorm Cell Therapeutics	BCLI		–$4.49 M	–$0.70	$28.8 M	2021
Caladrius Biosciences.	CLBS		–$5.3 M	–$0.29	$40.3 M	Q2/21
Cellectis SA	CLLS		–$30 M	–$0.71	$308 M	2022
CRISPR Therapeutics	CRSP		–$92.4 M	–$1.32	$1.4 B	2023
Editas Medicine	EDIT	+7.8 M or +$0.12			$541.3 M	2023
Fate Therapeutics	FATE		–$58.6 M	–$0.68	$502 M	2022
Global Blood Therapeutics	GBT		–$59.9 M	–$0.97	$535.2 M	2024
Homology Medicine	FIXX		–$28.2 M	–$0.62	$178 M	2022
Intellia Therapeutics	NTLA		–$27.8 M	–$0.47	$407.9 M	2022
Precigen formerly Intrexon	PGEN		–$29.5 M	–$0.18	$113.1 M	2021
Ionis Pharmaceuticals	IONS		–$14.5 M	–$7.00	$2.35 B	N/A
Mesoblast	MESO		–$X M	–$X	$X M
MiMedx Group	MDXG		–$19.4 M	–$0.48	$109.6 M	Q2/2022
Pluristem Therapeutics	PSTI		–$X M	–$X	$59 M	2021
ReNeuron Group	RENE.L
Regenxbio	RGNX		–$8.8 M	–$0.24	$289.8 M	mid-22
Sage Therapeutics	SAGE		–$105.7 M	–$2.03	$671 M	2022
Sangamo Biosciences	SGMO		–$1.6 M	–$0.01	$694.5 M	2022
Solid Biosciences	SLDB		–$21.2 M	–$0.44	$24.8 M	2H/21
StemlineTherapeutics	STML	Acquired by Menarini, an Italian pharma
Ultragenyx	RARE		-$68.8 M	-$1.13	$7.65 M	N/A
uniQure N.V.	QURE		–$53.8 M	–$1.21	$279.5 M	2h/24
Verastem	VSTM		–$1.31 M	–$0.08	$205.7 M	2024
Vericel	VCEL		–$3.6 M	–$0.08	$85.5 M	2022
Voyager Therapeutics	VYGR	+$85.6 M or +2.27			$200 M	mid-2022

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.